Novo Nordisk

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – BGI and Novo Nordisk today announced a collaboration to create a "global collaboration framework."

Movers & Shakers

Premium

Marc Voigt, Lars Rebien Sorensen, Robert McBurney

The Danish drug developer will use TET Systems' gene expression tools at its research institute.

The Novo Nordisk-funded center will use proteomics and other approaches for disease studies.

The diabetes care company will use the software under a multi-year agreement.

Two top BioMed officials told investors that stronger activity at two nearly-completed Northeast projects and a stash of cash will enable it to continue paying customary dividends, though conceded a slowdown in Bay Area leasing.

Seahorse acquired the maker of the SimCell System, a fully integrated cell culture automation system used for selecting clones, optimizing media, and determining the best process conditions for protein manufacturing, for an undisclosed sum. It also raised $6 million in funding from VC investors.

Top executives last week from Alexandria Real Estate Equities, BioMed Realty Trust, and HCP said life-sci shops are increasingly skittish about leasing new space for the long term, leading the REITs to reduce spending on construction and renovation projects this year.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.